Release Date: November 14, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Congrats on the progress, especially on accelerating enrollment in the Ovaprene study. Are we still expecting an interim look by the end of Q2 2025, and what should we expect from this interim readout? Just safety, or can we learn about efficacy too? A: Yes, the interim look is an important milestone. The study is open-label, meaning everyone receives the active product, which allows us to monitor safety continuously. The specifics of what will be reviewed and disclosed are still being discussed with our commercialization collaborator, Bayer, and the data safety monitoring board. The contraceptive rates tend to improve over time, so we need to consider how to handle any interim data.
Q: Can you share more about what you mean by operational progress towards phase three for Sildenafil Cream, and what is still outstanding with the FDA? A: Our discussions with the FDA have focused on defining appropriate endpoints for the phase three program, as this is a first-in-category product. We are working to ensure alignment on expectations for efficacy and safety. Operationally, we are preparing by identifying CROs, sites, and ensuring drug supply, so we are ready to proceed once we have alignment with the FDA.
Q: Regarding the Ovaprene trial and potential interim analysis, what specific actions might follow from this analysis? A: The DSMB is primarily monitoring safety, and the interim analysis will be conducted when we have enough patients and cycles to review. The timing is significant because contraceptive studies typically require a minimum of six months of data. We are considering how to handle the data review and any potential disclosures, especially given the known improvements in contraceptive rates over time.
Q: With the additional funding for the Ovaprene study, how many additional sites do you plan to add? A: We currently have 20 sites under the NIH's clinical trial network, with recruitment focused on about half of them. The additional funding will allow us to add a handful of new sites, which can significantly impact enrollment given the efficiency of the sites we've selected based on past performance.
Q: For Sildenafil Cream, once you have FDA alignment and funding, how soon could you initiate the trial? A: After aligning with the FDA on the final protocol, traditional study startup activities like site contracts and IRB approvals will take a couple of months. If funding is secured, starting the trial early next year is possible.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.